Sorafenib Tosylate Powder

تفاصيل المنتج

Sorafenib tosylate powder is a novel multi-targeted oral drug for the treatment of tumors. Its primary development goals are for the treatment of gastrointestinal stromal tumors and metastatic renal cells that do not respond to or are intolerant to standard therapy. Receptors that selectively target certain proteins, which are thought to act as a molecular switch during tumor growth.

The upstream product of Sorafenib is 4-(4-aminophenoxy)-N-methyl-2-pyridinecarboxamide, brown powder, “Pharmaceutical Raw Material Sorafenib Tosylate Powder” CAS 284462-37- 9 Sorafenib tosylate powder” is one of the essential intermediates for the synthesis of the tumor drug Sorafenib. This process includes chlorination, reflux, vacuum distillation, filtration, water washing, extraction, drying, etc.

الفوائد الصحية

It has dual anti-tumor effects: it can directly inhibit the proliferation of tumor cells by blocking the cell signaling pathway mediated by RAF/MEK/ERK, and it can also inhibit the proliferation of tumor cells by inhibiting VEGF and platelet-derived growth factor (PDGF) receptors. Block the formation of tumor angiogenesis and indirectly inhibit the growth of tumor cells. The drug is indicated for the treatment of unresectable hepatocellular carcinoma, advanced renal cell carcinoma, and locally recurrent or metastatic, progressive, differentiated thyroid cancer that is difficult to treat with radioactive iodine.

• Treatment of inoperable advanced renal cell carcinoma.
• Treatment of inoperable or distant metastatic hepatocellular carcinoma.
• Treatment of progressive radioactive iodine-refractory differentiated thyroid cancer with local recurrence or metastasis.